T1	Participants 413 460	from several studies totaling over 450 patients
T2	Participants 755 786	Seventy-eight patients with AFF
T3	Participants 928 954	All patients then received
T4	Participants 1131 1176	Both CaCl(2) and placebo pre-treatment groups
T5	Participants 1292 1324	One patient in the placebo group
T6	Participants 1418 1470	CaCl(2) seems to be equally safe compared to placebo
